A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Pharmacokinetics, Safety, and Antiviral Activity of JNJ-63623872 in Combination With Oseltamivir in Adult, and Elderly Hospitalized Patients With Influenza A Infection

Trial Profile

A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Pharmacokinetics, Safety, and Antiviral Activity of JNJ-63623872 in Combination With Oseltamivir in Adult, and Elderly Hospitalized Patients With Influenza A Infection

Completed
Phase of Trial: Phase II

Latest Information Update: 28 Jun 2017

At a glance

  • Drugs Pimodivir (Primary) ; Oseltamivir
  • Indications Influenza A virus infections
  • Focus Pharmacokinetics
  • Acronyms OPAL
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 22 Jun 2017 Status changed from active, no longer recruiting to completed.
    • 03 Jun 2017 This trial has been completed in Spain (end date: 15 Mar 2017).
    • 19 May 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top